Ernexa Therapeutics Inc.
ERNA · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.02 | -0.00 | 0.07 | 0.11 |
| FCF Yield | -14.30% | -26.57% | -1.45% | -1.56% |
| EV / EBITDA | -5.53 | -2.37 | -53.90 | -102.67 |
| Quality | ||||
| ROIC | -47.07% | -48.56% | 93.62% | -106.26% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 100.00% |
| Cash Conversion Ratio | 1.03 | 0.81 | 0.25 | 0.62 |
| Growth | ||||
| Revenue 3-Year CAGR | -73.03% | 787,199.44% | 811,704.14% | 834,812.56% |
| Free Cash Flow Growth | 48.89% | -22.62% | 41.75% | 43.77% |
| Safety | ||||
| Net Debt / EBITDA | 2.10 | 1.52 | -0.36 | 0.48 |
| Interest Coverage | -64.29 | 0.00 | 0.00 | -0.77 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 39,330.00 |